← Back to Search

Knee Joint Effusion for Knee Injuries

N/A
Recruiting
Research Sponsored by Duke University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Tegner Activity Scale score at least 5/10
Chronological age 18-35 at the time of study participation
Must not have
Currently taking pain altering medication
History of lower extremity or lumbar spine surgery
Timeline
Screening 3 weeks
Treatment Varies
Follow Up immediately pre- (10 minutes) and post- (10 minutes) effusion
Awards & highlights
No Placebo-Only Group

Summary

This trial will test the efficacy of a wearable sensor in detecting changes in lower extremity biomechanics due to a common clinical change in joint status.

Who is the study for?
This trial is for healthy adults aged 18-35 who are physically active, with a moderate level of engagement in sports or physical activities. Ideal candidates should not have any major knee injuries, neurological conditions, autoimmune diseases, cardiovascular issues, or be on pain medication. Pregnant individuals and those with recent lower extremity surgeries or injuries are excluded.
What is being tested?
The study aims to test the effectiveness of a wearable sensor in detecting changes in knee joint loading by artificially inducing swelling (effusion) within the knee joint. Participants will undergo tests that measure thigh and shank movement, muscle function during walking, balance, and subjective outcomes before and after this induced change.
What are the potential side effects?
Potential risks include discomfort from the experimental effusion procedure which involves introducing fluid into the knee joint under sterile conditions. The participants will be monitored for any adverse effects following the session.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My activity level is moderate or higher.
Select...
I am between 18 and 35 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently on medication to manage pain.
Select...
I have had surgery on my lower back or legs.
Select...
I have had a leg or lower back injury in the last 6 months.
Select...
I have a neurological, autoimmune, or heart condition.
Select...
I am experiencing knee pain.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~immediately pre- (10 minutes) and post- (10 minutes) effusion
This trial's timeline: 3 weeks for screening, Varies for treatment, and immediately pre- (10 minutes) and post- (10 minutes) effusion for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Peak Internal Knee Extension Moment
Change in Peak Knee Power
Change in Peak Vertical Ground Reaction Force
+4 more
Secondary study objectives
Change in Hamstring EMG
Change in International Knee Documentation Committee
Change in Quadriceps EMG
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Knee Joint EffusionExperimental Treatment1 Intervention
Participants will receive a one-time injection of 60mL of sterile saline into the suprapatellar space of the dominant lower extremity. This injection will be conducted under ultrasound guidance by a board-certified orthopedic surgeon.

Find a Location

Who is running the clinical trial?

Duke UniversityLead Sponsor
2,455 Previous Clinical Trials
2,971,527 Total Patients Enrolled
3 Trials studying Knee Injuries
721 Patients Enrolled for Knee Injuries

Media Library

Knee Joint Effusion Clinical Trial Eligibility Overview. Trial Name: NCT03805464 — N/A
Knee Injuries Research Study Groups: Knee Joint Effusion
Knee Injuries Clinical Trial 2023: Knee Joint Effusion Highlights & Side Effects. Trial Name: NCT03805464 — N/A
Knee Joint Effusion 2023 Treatment Timeline for Medical Study. Trial Name: NCT03805464 — N/A
~0 spots leftby Dec 2024